Remsima

Remsima
Product Description

The world's 1st mAb biosimilar

  • Ingredient: Infliximab
  • Indication: Rheumatoid arthritis, inflammatory bowel disease
  • Mode of mechanism: Relieves disease progression by inducing a neutralizing response to tumor necrosis factor(TNF-α), the cause of autoimmune disease
  • Approval status: 100 countries including the US(product name: Inflectra), Europe and South Korea 

Read more Show less

Celltrion

  • KR
  • 2022
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less

Celltrion

  • KR
  • 2022
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Primary activities
Biopharmaceutical
View company profile

More Products from Celltrion (4)

  • Remsima SC

    Product Remsima SC

    The 1st subcutaneous formulation of infliximab • Ingredient: Infliximab  • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Alleviate disease progression by inducing a neutralizing reaction to TNF-α, the cause of autoimmune disease • Approval status: 49 countries in...
  • Truxima

    Product Truxima

    • Ingredient: Rituximab • Indication: Non-Hodgkin's lymphoma, rheumatoid arthritis • Mode of mechanism: Specifically binds to CD20, which is expressed on the cell surface of human B cells and lyses target cells to express pharmacological action with mechamisms such as complement-dependent cytotoxicity, ...
  • Herzuma

    Product Herzuma

    • Ingredient: Trastuzumab • Indication: Breast cancer, stomach cancer • Mode of mechanism: Inhibits tumor cell proliferation and growth by binding to a specific antigen (HER2) that occurs specifically and excessively on the surface of tumor cells  • Approval status: 80 countries including US, Euro...
  • Yuflyma

    Product Yuflyma

    • Ingredient: Adalimumab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Blocks the transmission of inflammatory signals by binding to TNF-α in the body   • Approval status: 44 countries including the US(product name: Inflectra), Europe and South Korea 

Celltrion resources (2)